Navigation Links
GeneNews Announces First Quarter Results
Date:5/2/2008

tioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.

CONSOLIDATED BALANCE SHEETS

(Unaudited)

(Expressed in Canadian dollars)

As at

March 31 December 31

2008 2007

$ $

-------------------------------------------------------------------------

ASSETS

Current

Cash and cash equivalents 9,116,406 11,279,030

Short-term investment 400,000 400,000

Accounts receivable 1,118,151 1,582,242

Investment tax credits recoverable 573,618 1,038,199

Prepaid expenses and deposits 558,783 512,914

-------------------------------------------------------------------------

Total current assets 11,766,958 14,812,385

-------------------------------------------------------------------------

Property, plant and equipment, net 3,700,464 3,635,245

Intellectual property, net 292,547 400,380

-------------------------------------------------------------------------

15,759,968 18,848,010

-------------------------------------------------------------------------

-------------------------------------------------------------------------

LIABILITIES AND SHAREHOLDERS' EQUITY

Current

Accounts payable and accrued liabilities 1,461,582 1,699,153

Deferred revenue 1,210,514 1,204,305

Cu
'/>"/>

SOURCE GeneNews Limited
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. GeneNews CSO Dr. CC Liew awarded state honour by the Government of Malaysia
2. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
3. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
4. GeneNews receives ISO 13485 accreditation
5. GeneNews selected to present late-breaking abstract at AACR Annual Meeting
6. GeneNews announces 2007 year end results
7. GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email: